RxDoctor Payments DataLook up a doctor →

Ramon Reyes, MD

Family Medicine · Boerne, TXNPI 1811984727

Payments from drug & device makers

$3,836,125in general payments, 2019–2025

Across 1,144 payments — averaging $3353.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Regeneron$1.1M
  • Emergent Biosolutions Inc.$736K
  • AstraZeneca$494K
  • Bavarian Nordic A/s$337K
  • Braintree Laboratories, Inc.$303K
  • Eli Lilly$242K
  • plus $639K from 54 others
$12,119in research payments, 2019–2025

Across 7 payments — averaging $1731.23 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$12K

What the payments were for

  • Consulting fees$17,33434%
  • Speaking & faculty fees$5,50011%
  • Travel & lodging$13,63327%
  • Food & beverage$14,57128%
  • Education$530%
  • Gifts$590%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Regeneron83$1,084,933
Emergent Biosolutions Inc.42$735,930
AstraZeneca109$494,346
Bavarian Nordic A/s37$337,121
Braintree Laboratories, Inc.21$302,878
Eli Lilly18$241,522
Kowa Research Institute, Inc.57$164,099
Pfizer67$124,735
Novo Nordisk AS12$96,177
Sanofi US Services Inc.17$86,330
Amgen(2 entities)127$65,468
Radius Health, Inc.43$40,749
Teva Pharmaceuticals USA, Inc.13$22,169
Astrazeneca UK Limited7$14,912
Amarin Pharma, Inc.11$10,080
Astrazeneca AB1$3,800
Lexicon Pharmaceuticals, Inc.2$2,590
AbbVie(2 entities)160$2,381
Novo Nordisk70$996
Intuitive Surgical5$783
Lilly USA, LLC52$657
Johnson & Johnson(2 entities)31$515
GSK19$389
Sanofi-aventis U.S. LLC24$359
Biohaven Pharmaceuticals, Inc.10$266
Esperion Therapeutics, Inc.7$207
Boehringer Ingelheim10$175
Bayer7$141
Novartis8$120
Exact Sciences5$90
Cequr Corporation2$83
Astellas Pharma US Inc5$81
Abbott4$71
Axsome Therapeutics, Inc.2$64
Antares Pharma, Inc.4$63
Merck4$61
Mannkind Corporation1$59
Biohaven Pharmaceutical Holding Company Ltd.3$56
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC4$54
Sunovion Pharmaceuticals Inc.4$53
Takeda Pharmaceuticals U.S.A., Inc.5$52
Genentech USA, Inc.3$50
Medtronic2$45
Avanir Pharmaceuticals, Inc.3$39
Shire North American Group Inc2$36
Solventum Corporation1$28
Tolmar, Inc.2$28
IBSA Pharma Inc.2$27
Acerus Pharmaceuticals Corporation2$26
Nalpropion Pharmaceuticals LLC2$23
Philips North America LLC1$21
Dexcom, Inc.1$21
Eisai Inc.1$20
Halozyme Inc1$19
Adlon Therapeutics L.p.1$19
Nestle Healthcare Nutrition Inc.1$17
Mylan Specialty L.p.1$16
Clarus Therapeutics Inc.1$16
Supernus Pharmaceuticals, Inc.1$16
Hikma Pharmaceuticals USA1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,836,125 in reported general payments places this provider in the 95th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$164,939
Medicare patients
360
Services billed
5,496

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin230$325,345
MounjaroTirzepatide283$319,221
OzempicSemaglutide160$230,915
ProliaDenosumab128$226,584
TrulicityDulaglutide71$92,973
Trelegy ElliptaFluticasone/Umeclidin/Vilanter81$85,486
Bydureon BciseExenatide Microspheres84$71,130
EliquisApixaban47$64,849
OtezlaApremilast11$62,556
BiktarvyBictegrav/Emtricit/Tenofov Ala15$57,195
TymlosAbaloparatide20$52,924
Evenity (2 Syringes)Romosozumab-Aqqg20$49,699
XareltoRivaroxaban41$45,666
Soliqua 100-33Insulin Glargine/Lixisenatide49$43,450
FarxigaDapagliflozin Propanediol56$40,768

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$657$412,194354 claims
Boehringer IngelheimJardiance, Spiriva Respimat$175$340,680259 claims
AmgenProlia, Otezla, Evenity (2 Syringes)$65,468$338,839159 claims
Novo NordiskOzempic, Wegovy$996$247,641173 claims
GSKTrelegy Ellipta, Anoro Ellipta$389$96,75497 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$494,346$85,653125 claims
PfizerEliquis$124,735$64,84947 claims
Radius Health, Inc.Tymlos$40,749$52,92420 claims
AbbVieVraylar, Linzess$2,381$52,54447 claims
Johnson & JohnsonXarelto$515$45,66641 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$359$43,45049 claims
Astellas Pharma US IncMyrbetriq$81$29,46128 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Boerne

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →